AGŐćČ˹ٷ˝

STOCK TITAN

Penumbra Inc SEC Filings

PEN NYSE

Welcome to our dedicated page for Penumbra SEC filings (Ticker: PEN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.

Locating R&D spend for Penumbra’s Lightning Flash thrombectomy platform or tracking how stroke-care sales trend across 100+ countries can feel like navigating a catheter through tight anatomy. The company’s disclosures span hundreds of pages, and the detail investors need—product line revenue, pipeline milestones, or 510(k) updates—often hides deep inside footnotes.

Stock Titan turns that complexity into clarity. Our AI reads every Penumbra annual report 10-K simplified, each Penumbra quarterly earnings report 10-Q filing, and even the swift Penumbra 8-K material events explained, then extracts what matters. Need Penumbra insider trading Form 4 transactions before market open? We send alerts the moment a Penumbra Form 4 insider transactions real-time hits EDGAR. Wonder how directors are paid? The Penumbra proxy statement executive compensation is summarized in plain English. For fast answers, just ask â€�understanding Penumbra SEC documents with AIâ€� or â€�Penumbra earnings report filing analysisâ€� and jump straight to the insight.

What you’ll uncover here:

  • Device segment revenue shifts across neurovascular and peripheral vascular markets
  • Regulatory milestones that could accelerate sales growth
  • Penumbra executive stock transactions Form 4 patterns around product launches

Whether you’re screening for valuation catalysts or monitoring compliance risk, this page delivers every filing�10-K, 10-Q, 8-K, S-8, and more—with real-time updates and AI-powered summaries that explain filing meanings in simple terms. No more PDF scavenging; the critical data on Penumbra SEC filings explained simply is already parsed and ready for decision-making.

Filing
Rhea-AI Summary

Bitcoin Depot Inc. (Nasdaq: BTM) has filed a shelf registration statement on Form 424B5 allowing it to issue up to $100 million in securities, including Class A common stock, preferred stock, warrants and/or units, in one or more offerings. Specific terms, pricing and underwriters will be disclosed in future prospectus supplements.

Capital structure & potential dilution: The company currently has 22,555,710 Class A shares outstanding, 41,193,024 Class M shares (10 votes per share) controlled by the CEO, and 43,848,750 warrants exercisable at $11.50 until June 30 2033. Any issuance under the shelf could materially increase the public float and dilute existing holders, though proceeds will fund “general corporate purposes.â€�

Business snapshot: Bitcoin Depot operates the largest Bitcoin ATM (BTM) network in North America with 8,483 kiosks and BDCheckout access in 10,926 retail locations as of March 31 2025. Q1 2025 revenue was $164.2 million, up from $138.5 million in Q1 2024, yet the company notes a 9.7 % revenue decline on a trailing-twelve-month basis despite a 15.7 % rise in Bitcoin prices, underscoring limited correlation between revenue and crypto price movements.

Key relationships & competitive position: The firm is the exclusive BTM provider for approximately 900 U.S. and Canadian Circle K stores and also licenses its BitAccess processing software to third-party operators, generating recurring software revenue.

Risk highlights (summarised from filing):

  • High dilution risk from additional equity or equity-linked issuances.
  • Complex, multi-class share structure with super-voting Class M and Class V shares.
  • Regulatory, competitive and litigation uncertainties outlined under “Risk Factors.â€�
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
other
-
Rhea-AI Summary

Penumbra, Inc. (PEN) â€� Form 4 insider transaction

Executive Vice President, General Counsel & Secretary Johanna Roberts reported the exercise of employee stock options on 25 June 2025 (transaction code M). She converted 1,943 stock-option units with an exercise price of $22.04 into an equal number of common shares. All options were already fully vested and would have expired on 11 Aug 2025.

Following the exercise, Roberts� direct beneficial ownership increased to 66,657 PEN shares. No derivative securities remain outstanding from this grant, and the filing discloses no concurrent sale of the acquired shares.

The transaction was filed individually by the reporting person on 27 June 2025.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
-
Rhea-AI Summary

Penumbra (NYSE:PEN) filed a Form 4 detailing insider transactions by CEO Adam Elsesser.

  • Options exercised: 27,976 shares at $30
  • Shares sold: 15,890 at an average â‰�$253; gross proceeds â‰�$4.0 million
  • Ownership after trade: 122,441 direct shares and 577,582 indirect shares via trust (â‰�700k total)
  • Sale magnitude: ~2.3% of post-transaction holdings but above the $1 million materiality threshold

Sales were executed under a pre-arranged Rule 10b5-1 plan tied to option expiration on 09/16/2025, suggesting liquidity and tax-coverage motives rather than discretionary selling.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
Filing
Rhea-AI Summary

Form 144 Notice of Proposed Sale filed by Adam Elsesser of Penumbra indicates planned sale of 15,890 shares of common stock with an aggregate market value of $4,026,584.79. The sale is scheduled for June 25, 2025, through Morgan Stanley Smith Barney LLC on the NYSE.

The shares were acquired through a stock option exercise on June 25, 2025, with cash payment. The filing reveals significant recent selling activity by Elsesser over the past 3 months:

  • June 11, 2025: 15,910 shares for $4.04M
  • May 28, 2025: 16,300 shares for $4.37M
  • May 14, 2025: 16,600 shares for $4.95M
  • May 7, 2025: 16,650 shares for $4.82M
  • April 16, 2025: 16,560 shares for $4.54M
  • April 2, 2025: 16,565 shares for $4.51M

Total shares outstanding: 38,725,940. The seller affirms no knowledge of undisclosed material adverse information regarding Penumbra's operations.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
other
-
Rhea-AI Summary

Penumbra Director Bridget O'Rourke reported a Form 4 filing disclosing the sale of 50 shares of common stock at a price of $259.78 per share on June 16, 2025. The transaction was executed under a pre-established Rule 10b5-1 trading plan, which provides a safe harbor from insider trading allegations.

Following the transaction, O'Rourke maintains beneficial ownership of 5,373 shares held directly, with a portion subject to vesting restrictions. The filing was submitted on June 28, 2025, within the required reporting timeframe.

  • Transaction Type: Sale of Common Stock
  • Total Transaction Value: $12,989
  • Ownership Form: Direct
  • Role: Director
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider

FAQ

What is the current stock price of Penumbra (PEN)?

The current stock price of Penumbra (PEN) is $249.74 as of July 2, 2025.

What is the market cap of Penumbra (PEN)?

The market cap of Penumbra (PEN) is approximately 9.8B.

What is the core business of Penumbra Inc.?

Penumbra Inc. specializes in designing, developing, manufacturing, and marketing innovative medical devices for neurovascular and peripheral vascular interventions.

What type of products does Penumbra offer?

The company offers a diverse portfolio that includes computer-assisted vacuum thrombectomy systems, neurovascular access devices, embolization tools, and additional devices for complex vascular conditions.

How do Penumbra's products improve clinical outcomes?

By integrating advanced technologies such as dual clot detection and modulated aspiration, Penumbra's devices enable faster, safer procedures, reducing blood loss and enhancing overall treatment efficacy.

In which markets does Penumbra operate?

Penumbra serves a global customer base, with significant operations in North America, Europe, Asia, and Australia, and is active in over 100 countries.

What sets Penumbra's technology apart from competitors?

Penumbra's advanced algorithms and innovative catheter designs, exemplified by its Lightning Flash and Lightning Bolt systems, provide superior control and efficiency in clot removal.

How does Penumbra support healthcare providers?

The company emphasizes continuous innovation and rigorous quality testing, ensuring that its devices meet high clinical standards and help healthcare providers perform procedures more safely and effectively.

What role does research and development play at Penumbra?

R&D is integral to Penumbra's operational model, driving continuous improvements in product design and ensuring the company remains at the forefront of medical technology innovation.

How is the business model of Penumbra structured?

Penumbra operates through an integrated model that combines R&D, manufacturing, and marketing, allowing for efficient product development and strong market execution across its global operations.
Penumbra Inc

NYSE:PEN

PEN Rankings

PEN Stock Data

9.81B
37.34M
3.93%
92.35%
3.52%
Medical Devices
Surgical & Medical Instruments & Apparatus
United States
ALAMEDA